You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBetaxolol
Accession NumberDB00195  (APRD00245)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioselective beta-1-adrenergic antagonist with no partial agonist activity. [PubChem]
Structure
Thumb
Synonyms
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol
1-(Isopropylamino)-3-[P-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Betaxololum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betaxolol Hydrochloridesolution/ drops5.6 mg/mLophthalmicSandoz Inc2000-05-15Not applicableUs
Betoptic Liqliquid0.5 %ophthalmicAlcon Canada Inc1986-12-311997-07-31Canada
Betoptic Ssuspension/ drops2.8 mg/mLophthalmicAlcon Laboratories, Inc.1996-01-15Not applicableUs
Betoptic S Oph Sus 0.25%suspension.25 %ophthalmicAlcon Canada Inc1994-12-31Not applicableCanada
Novo-betaxololliquid0.5 %ophthalmicNovopharm LimitedNot applicableNot applicableCanada
Sandoz Betaxololsolution0.5 %ophthalmicSandoz Canada Incorporated1998-11-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betaxololtablet, film coated20 mg/1oralGolden State Medical Supply, Inc.2008-06-27Not applicableUs
Betaxololtablet, film coated20 mg/1oralEpic Pharma LLC2010-07-20Not applicableUs
Betaxololtablet, film coated10 mg/1oralPhysicians Total Care, Inc.2003-10-07Not applicableUs
Betaxololsolution/ drops5 mg/mLophthalmicAkorn, Inc.2003-04-01Not applicableUs
Betaxololtablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2008-06-27Not applicableUs
Betaxololtablet, film coated10 mg/1oralEpic Pharma LLC2010-07-20Not applicableUs
Betaxolol Hydrochloridetablet, coated10 mg/1oralKvk Tech, Inc.2011-11-02Not applicableUs
Betaxolol Hydrochloridetablet, coated20 mg/1oralKvk Tech, Inc.2011-11-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetaxonNot Available
BetopticNot Available
KerloneNot Available
Brand mixtures
NameLabellerIngredients
Betoptic/piloAlcon Canada Inc
Salts
Name/CASStructureProperties
Betaxolol Hydrochloride
63659-19-8
Thumb
  • InChI Key: CHDPSNLJFOQTRK-UHFFFAOYNA-N
  • Monoisotopic Mass: 343.191421538
  • Average Mass: 343.889
DBSALT000328
Categories
UNIIO0ZR1R6RZ2
CAS number63659-18-7
WeightAverage: 307.4278
Monoisotopic: 307.214743799
Chemical FormulaC18H29NO3
InChI KeyInChIKey=NWIUTZDMDHAVTP-UHFFFAOYSA-N
InChI
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
IUPAC Name
1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tyrosols and derivatives. These are compounds containing a hydroxyethyl group attached to the C4 carbon of a phenol group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentTyrosols and derivatives
Alternative Parents
Substituents
  • Tyrosol derivative
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of hypertension.
PharmacodynamicsBetaxolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Betaxolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as betaxolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Betaxolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity.
Mechanism of actionBetaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Betaxolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.
Related Articles
AbsorptionAbsorption of an oral dose is complete. There is a small and consistent first-pass effect resulting in an absolute bioavailability of 89% ± 5% that is unaffected by the concomitant ingestion of food or alcohol.
Volume of distributionNot Available
Protein binding50%
Metabolism

Primarily hepatic. Approximately 15% of the dose administered is excreted as unchanged drug, the remainder being metabolites whose contribution to the clinical effect is negligible.

Route of eliminationNot Available
Half life14-22 hours
ClearanceNot Available
ToxicityOral LD50s are 350 to 400 mg betaxolol/kg in mice and 860 to 980 mg/kg in rats. Predicted symptoms of overdose include bradycardia, congestive heart failure, hypotension, bronchospasm, and hypoglycemia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Betaxolol Action PathwayDrug actionSMP00299
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9903
Blood Brain Barrier-0.8906
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7683
P-glycoprotein inhibitor INon-inhibitor0.7967
P-glycoprotein inhibitor IINon-inhibitor0.8547
Renal organic cation transporterNon-inhibitor0.8206
CYP450 2C9 substrateNon-substrate0.8106
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7221
CYP450 1A2 substrateInhibitor0.8972
CYP450 2C9 inhibitorInhibitor0.5241
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9249
CYP450 3A4 inhibitorNon-inhibitor0.9647
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9741
Ames testNon AMES toxic0.8765
CarcinogenicityNon-carcinogens0.9304
BiodegradationNot ready biodegradable0.9395
Rat acute toxicity2.1620 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7663
hERG inhibition (predictor II)Non-inhibitor0.7498
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • Novex pharma
  • Wockhardt ltd
  • Alcon laboratories inc
  • Epic pharma llc
  • Kvk tech inc
  • Sanofi aventis us llc
  • Alcon inc
Packagers
Dosage forms
FormRouteStrength
Solution/ dropsophthalmic5 mg/mL
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Solution/ dropsophthalmic5.6 mg/mL
Tablet, coatedoral10 mg/1
Tablet, coatedoral20 mg/1
Liquidophthalmic0.5 %
Suspension/ dropsophthalmic2.8 mg/mL
Suspensionophthalmic.25 %
Suspensionophthalmic
Solutionophthalmic0.5 %
Prices
Unit descriptionCostUnit
Betoptic-S 0.25% Suspension 15ml Bottle195.44USD bottle
Betoptic-S 0.25% Suspension 10ml Bottle130.29USD bottle
Betaxolol HCl 0.5% Solution 15ml Bottle104.31USD bottle
Betoptic-S 0.25% Suspension 5ml Bottle51.99USD bottle
Betoptic s 0.25% eye drops9.79USD ml
Betaxolol hcl 0.5% eye drop6.82USD ml
Betoptic S 0.25 % Suspension2.54USD ml
Kerlone 20 mg tablet2.35USD tablet
Betaxolol 20 mg tablet1.86USD tablet
Kerlone 10 mg tablet1.63USD tablet
Betaxolol HCl 10 mg tablet1.29USD tablet
Betaxolol 10 mg tablet1.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5540918 No1994-01-302014-01-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point70-72 °CPhysProp
water solubility451 mg/LNot Available
logP2.81RECANATINI,M (1992)
Caco2 permeability-4.81ADME Research, USCD
pKa9.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0298 mg/mLALOGPS
logP3ALOGPS
logP2.54ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity88.64 m3·mol-1ChemAxon
Polarizability37.05 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ramesh Joshi, Muthukrishnan Murugan, Dinesh Garud, Sanjay Borikar, Mukund Gurjar, “PROCESS FOR PREPARATION OF S-(-)-BETAXOLOL AND SALTS THEREOF.” U.S. Patent US20060004109, issued January 05, 2006.

US20060004109
General References
  1. Canotilho J, Castro RA: The structure of betaxolol studied by infrared spectroscopy and natural bond orbital theory. Spectrochim Acta A Mol Biomol Spectrosc. 2010 Aug;76(3-4):395-400. doi: 10.1016/j.saa.2010.03.038. Epub 2010 Apr 4. [PubMed:20418154 ]
External Links
ATC CodesC07AB05S01ED52S01ED02
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (111 KB)
MSDSDownload (38.8 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Betaxolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Betaxolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Betaxolol.
AbirateroneThe serum concentration of Betaxolol can be increased when it is combined with Abiraterone.
AcebutololBetaxolol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Betaxolol.
AcepromazineAcepromazine may increase the hypotensive activities of Betaxolol.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Betaxolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Acetazolamide.
AcetohexamideBetaxolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Acetylcholine.
AcetyldigitoxinBetaxolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Betaxolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Betaxolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Betaxolol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Betaxolol.
AlfuzosinBetaxolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Betaxolol.
AliskirenBetaxolol may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Betaxolol.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Betaxolol.
AlprenololBetaxolol may increase the hypotensive activities of Alprenolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Betaxolol.
AmbrisentanBetaxolol may increase the hypotensive activities of Ambrisentan.
AmifostineBetaxolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amiloride.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Betaxolol.
AminophyllineBetaxolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Betaxolol.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Betaxolol.
AmlodipineBetaxolol may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Betaxolol.
AmodiaquineThe metabolism of Betaxolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Betaxolol can be increased when it is combined with Amoxapine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Betaxolol.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Betaxolol.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Betaxolol.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Betaxolol.
Amyl NitriteThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Betaxolol.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Betaxolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Betaxolol.
AprindineThe metabolism of Aprindine can be decreased when combined with Betaxolol.
ArbutamineBetaxolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Arecoline.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Betaxolol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Betaxolol.
AripiprazoleAripiprazole may increase the hypotensive activities of Betaxolol.
ArtemetherThe metabolism of Artemether can be decreased when combined with Betaxolol.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Betaxolol.
AtenololBetaxolol may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Betaxolol can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Betaxolol.
AzelastineAzelastine may decrease the antihypertensive activities of Betaxolol.
AzelastineThe metabolism of Azelastine can be decreased when combined with Betaxolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Azilsartan medoxomil.
AzithromycinThe metabolism of Betaxolol can be decreased when combined with Azithromycin.
BalsalazideBalsalazide may decrease the antihypertensive activities of Betaxolol.
BambuterolBetaxolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Betaxolol.
BenazeprilBetaxolol may increase the hypotensive activities of Benazepril.
BendroflumethiazideBetaxolol may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Betaxolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Betaxolol.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Betaxolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Betaxolol.
BepridilBetaxolol may increase the hypotensive activities of Bepridil.
BeractantBetaxolol may increase the bradycardic activities of Beractant.
BethanecholThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bethanechol.
BethanidineBetaxolol may increase the hypotensive activities of Bethanidine.
BimatoprostBetaxolol may increase the hypotensive activities of Bimatoprost.
BisoprololBetaxolol may increase the hypotensive activities of Bisoprolol.
BortezomibThe metabolism of Betaxolol can be decreased when combined with Bortezomib.
BosentanBetaxolol may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the bradycardic activities of Betaxolol.
BretyliumBetaxolol may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Betaxolol.
BrimonidineBetaxolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Betaxolol.
BromfenacBromfenac may decrease the antihypertensive activities of Betaxolol.
BromocriptineBetaxolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Betaxolol.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Betaxolol.
BumetanideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.
BupranololBetaxolol may increase the hypotensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Betaxolol.
BupropionThe metabolism of Bupropion can be decreased when combined with Betaxolol.
BuspironeThe metabolism of Buspirone can be decreased when combined with Betaxolol.
CabergolineBetaxolol may increase the vasoconstricting activities of Cabergoline.
CaffeineThe metabolism of Betaxolol can be decreased when combined with Caffeine.
CalfactantBetaxolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Canagliflozin.
CandesartanBetaxolol may increase the hypotensive activities of Candesartan.
CandoxatrilBetaxolol may increase the hypotensive activities of Candoxatril.
CaptoprilBetaxolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Betaxolol is combined with Carbachol.
CarbamazepineThe metabolism of Betaxolol can be increased when combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Betaxolol.
CaroxazoneCaroxazone may increase the hypotensive activities of Betaxolol.
CarprofenCarprofen may decrease the antihypertensive activities of Betaxolol.
CarteololBetaxolol may increase the hypotensive activities of Carteolol.
CarvedilolBetaxolol may increase the hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Betaxolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Betaxolol.
CeliprololBetaxolol may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Betaxolol.
CeritinibBetaxolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Cevimeline.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Betaxolol.
ChloroquineChloroquine may decrease the antihypertensive activities of Betaxolol.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Betaxolol.
ChlorothiazideBetaxolol may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Betaxolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Betaxolol.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Betaxolol.
ChlorpropamideBetaxolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneBetaxolol may increase the hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Betaxolol.
CholecalciferolThe metabolism of Betaxolol can be decreased when combined with Cholecalciferol.
CilazaprilBetaxolol may increase the hypotensive activities of Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Betaxolol.
CimetidineThe metabolism of Betaxolol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Betaxolol can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Betaxolol.
CitalopramThe metabolism of Betaxolol can be decreased when combined with Citalopram.
ClemastineThe metabolism of Betaxolol can be decreased when combined with Clemastine.
ClenbuterolBetaxolol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Clevidipine.
ClobazamThe metabolism of Betaxolol can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Betaxolol can be increased when it is combined with Clomipramine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Betaxolol.
ClonidineBetaxolol may increase the hypotensive activities of Clonidine.
ClonixinClonixin may decrease the antihypertensive activities of Betaxolol.
ClotrimazoleThe metabolism of Betaxolol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Betaxolol.
CobicistatThe serum concentration of Betaxolol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Betaxolol can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Betaxolol.
CoumaphosCoumaphos may increase the bradycardic activities of Betaxolol.
CrizotinibBetaxolol may increase the bradycardic activities of Crizotinib.
CryptenamineBetaxolol may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Betaxolol.
CyclothiazideBetaxolol may increase the hypotensive activities of Cyclothiazide.
Cyproterone acetateThe serum concentration of Betaxolol can be decreased when it is combined with Cyproterone acetate.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Betaxolol.
DapagliflozinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Betaxolol can be increased when it is combined with Dapoxetine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Betaxolol.
DarunavirThe serum concentration of Betaxolol can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Betaxolol.
DebrisoquinBetaxolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Betaxolol.
DeferasiroxThe serum concentration of Betaxolol can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Betaxolol.
DemecariumDemecarium may increase the bradycardic activities of Betaxolol.
DeserpidineBetaxolol may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Betaxolol.
DeslanosideBetaxolol may increase the bradycardic activities of Deslanoside.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Betaxolol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Betaxolol.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Betaxolol.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Betaxolol.
DiazoxideDiazoxide may increase the hypotensive activities of Betaxolol.
DichlorvosDichlorvos may increase the bradycardic activities of Betaxolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Betaxolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Betaxolol.
DigitoxinBetaxolol may increase the bradycardic activities of Digitoxin.
DigoxinBetaxolol may increase the bradycardic activities of Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Betaxolol.
DihydroergotamineBetaxolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
DiltiazemBetaxolol may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dinutuximab.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Betaxolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Betaxolol.
DipivefrinBetaxolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Betaxolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Betaxolol.
DobutamineBetaxolol may decrease the bronchodilatory activities of Dobutamine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Betaxolol.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Betaxolol.
DonepezilDonepezil may increase the bradycardic activities of Betaxolol.
DopamineThe metabolism of Dopamine can be decreased when combined with Betaxolol.
DorzolamideBetaxolol may increase the hypotensive activities of Dorzolamide.
DoxazosinBetaxolol may increase the hypotensive activities of Doxazosin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Betaxolol.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Betaxolol.
DronedaroneBetaxolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Betaxolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Betaxolol.
DroxidopaBetaxolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineBetaxolol may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Betaxolol can be decreased when combined with Duloxetine.
DyphyllineBetaxolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Betaxolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Betaxolol.
EfonidipineBetaxolol may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Betaxolol.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Betaxolol.
EmpagliflozinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Empagliflozin.
EnalaprilBetaxolol may increase the hypotensive activities of Enalapril.
EnalaprilatBetaxolol may increase the hypotensive activities of Enalaprilat.
EncainideThe metabolism of Encainide can be decreased when combined with Betaxolol.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Betaxolol.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Betaxolol.
EphedraBetaxolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Betaxolol is combined with EPIBATIDINE.
EpinastineThe metabolism of Epinastine can be decreased when combined with Betaxolol.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
EpinephrineBetaxolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Betaxolol.
EplerenoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Eplerenone.
EpoprostenolBetaxolol may increase the hypotensive activities of Epoprostenol.
EprosartanBetaxolol may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateBetaxolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineBetaxolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineBetaxolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Betaxolol.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Betaxolol.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Betaxolol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Betaxolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Betaxolol.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Betaxolol.
EtodolacEtodolac may decrease the antihypertensive activities of Betaxolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Betaxolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Betaxolol.
EtoperidoneThe serum concentration of Betaxolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Betaxolol.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Betaxolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Betaxolol.
exisulindexisulind may decrease the antihypertensive activities of Betaxolol.
FelodipineBetaxolol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Betaxolol.
FenfluramineThe serum concentration of Betaxolol can be increased when it is combined with Fenfluramine.
FenoldopamBetaxolol may increase the hypotensive activities of Fenoldopam.
FenoprofenFenoprofen may decrease the antihypertensive activities of Betaxolol.
FenoterolBetaxolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Betaxolol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Betaxolol.
FingolimodBetaxolol may increase the bradycardic activities of Fingolimod.
FlecainideThe metabolism of Flecainide can be decreased when combined with Betaxolol.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Betaxolol.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Betaxolol.
FlunixinFlunixin may decrease the antihypertensive activities of Betaxolol.
FluoxetineThe serum concentration of Betaxolol can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Betaxolol.
FluphenazineFluphenazine may increase the hypotensive activities of Betaxolol.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Betaxolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Betaxolol.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Betaxolol.
FluvoxamineThe metabolism of Betaxolol can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Betaxolol.
FosinoprilBetaxolol may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Betaxolol.
FurosemideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Furosemide.
GalantamineGalantamine may increase the bradycardic activities of Betaxolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Betaxolol.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Betaxolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Betaxolol.
GlibornurideBetaxolol may increase the hypoglycemic activities of Glibornuride.
GliclazideBetaxolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideBetaxolol may increase the hypoglycemic activities of Glimepiride.
GlipizideBetaxolol may increase the hypoglycemic activities of Glipizide.
GliquidoneBetaxolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideBetaxolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideBetaxolol may increase the hypoglycemic activities of Glyburide.
GranisetronThe metabolism of Granisetron can be decreased when combined with Betaxolol.
GTS-21The risk or severity of adverse effects can be increased when Betaxolol is combined with GTS-21.
GuanabenzBetaxolol may increase the hypotensive activities of Guanabenz.
GuanadrelBetaxolol may increase the hypotensive activities of Guanadrel.
GuanethidineBetaxolol may increase the hypotensive activities of Guanethidine.
GuanfacineBetaxolol may increase the hypotensive activities of Guanfacine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Betaxolol.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Betaxolol.
HalothaneThe metabolism of Halothane can be decreased when combined with Betaxolol.
HexamethoniumBetaxolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Betaxolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Betaxolol.
Huperzine AHuperzine A may increase the bradycardic activities of Betaxolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Betaxolol.
HydralazineBetaxolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideBetaxolol may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Betaxolol.
HydroflumethiazideBetaxolol may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Betaxolol.
HydroxychloroquineThe metabolism of Betaxolol can be decreased when combined with Hydroxychloroquine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Betaxolol.
IbuprofenIbuprofen may decrease the antihypertensive activities of Betaxolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Betaxolol.
IcatibantIcatibant may decrease the antihypertensive activities of Betaxolol.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Betaxolol.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Betaxolol.
IloprostIloprost may increase the hypotensive activities of Betaxolol.
ImatinibThe metabolism of Imatinib can be decreased when combined with Betaxolol.
ImipramineThe metabolism of Imipramine can be decreased when combined with Betaxolol.
IndacaterolBetaxolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Betaxolol can be increased when it is combined with Indalpine.
IndapamideBetaxolol may increase the hypotensive activities of Indapamide.
IndenololBetaxolol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Betaxolol can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Betaxolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Betaxolol.
IndoraminBetaxolol may increase the hypotensive activities of Indoramin.
Insulin PorkBetaxolol may increase the hypoglycemic activities of Insulin Pork.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Betaxolol.
IproclozideIproclozide may increase the hypotensive activities of Betaxolol.
IproniazidIproniazid may increase the hypotensive activities of Betaxolol.
IrbesartanBetaxolol may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Betaxolol.
IsoetarineBetaxolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Betaxolol.
IsoniazidThe metabolism of Betaxolol can be decreased when combined with Isoniazid.
IsoprenalineBetaxolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Betaxolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isoxsuprine.
IsradipineBetaxolol may increase the hypotensive activities of Isradipine.
IvabradineBetaxolol may increase the bradycardic activities of Ivabradine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Betaxolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Betaxolol.
KetoconazoleThe metabolism of Betaxolol can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Betaxolol.
KetorolacKetorolac may decrease the antihypertensive activities of Betaxolol.
LabetalolBetaxolol may increase the hypotensive activities of Labetalol.
LacidipineBetaxolol may increase the hypotensive activities of Lacidipine.
LacosamideBetaxolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideBetaxolol may increase the bradycardic activities of Lanreotide.
LatanoprostBetaxolol may increase the hypotensive activities of Latanoprost.
LeflunomideLeflunomide may decrease the antihypertensive activities of Betaxolol.
LercanidipineBetaxolol may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Levobunolol.
LevodopaBetaxolol may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe serum concentration of Betaxolol can be increased when it is combined with Levomilnacipran.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Betaxolol.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Betaxolol.
LidocaineThe metabolism of Betaxolol can be decreased when combined with Lidocaine.
LisinoprilBetaxolol may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Betaxolol.
LobelineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Lobeline.
LofexidineBetaxolol may increase the hypotensive activities of Lofexidine.
LomustineThe metabolism of Lomustine can be decreased when combined with Betaxolol.
LoperamideThe metabolism of Loperamide can be decreased when combined with Betaxolol.
LopinavirThe metabolism of Betaxolol can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Betaxolol.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Betaxolol.
LornoxicamLornoxicam may decrease the antihypertensive activities of Betaxolol.
LosartanBetaxolol may increase the hypotensive activities of Losartan.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Betaxolol.
Lu AA21004The serum concentration of Betaxolol can be increased when it is combined with Lu AA21004.
LucinactantBetaxolol may increase the bradycardic activities of Lucinactant.
LumefantrineThe metabolism of Betaxolol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Betaxolol.
MacitentanBetaxolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Betaxolol.
MalathionMalathion may increase the bradycardic activities of Betaxolol.
ManidipineBetaxolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Betaxolol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Betaxolol.
MebanazineMebanazine may increase the hypotensive activities of Betaxolol.
MecamylamineBetaxolol may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Betaxolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Betaxolol.
MefloquineMefloquine may increase the bradycardic activities of Betaxolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Betaxolol.
MemantineMemantine may increase the bradycardic activities of Betaxolol.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Betaxolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Betaxolol.
MesalazineMesalazine may decrease the antihypertensive activities of Betaxolol.
MesoridazineMesoridazine may increase the hypotensive activities of Betaxolol.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Betaxolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Betaxolol.
MethacholineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methacholine.
MethadoneThe metabolism of Methadone can be decreased when combined with Betaxolol.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Betaxolol.
MethazolamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Betaxolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Betaxolol.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Betaxolol.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Betaxolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyclothiazide.
MethyldopaBetaxolol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Betaxolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Betaxolol.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Betaxolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Betaxolol.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Betaxolol.
MetipranololBetaxolol may increase the hypotensive activities of Metipranolol.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Betaxolol.
MetolazoneBetaxolol may increase the hypotensive activities of Metolazone.
MetoprololBetaxolol may increase the hypotensive activities of Metoprolol.
MexiletineThe metabolism of Betaxolol can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Betaxolol.
MibefradilBetaxolol may increase the hypotensive activities of Mibefradil.
MidodrineBetaxolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Betaxolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Betaxolol.
MinaprineThe metabolism of Minaprine can be decreased when combined with Betaxolol.
MinoxidilBetaxolol may increase the hypotensive activities of Minoxidil.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Betaxolol.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Betaxolol.
MoclobemideMoclobemide may increase the hypotensive activities of Betaxolol.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Betaxolol.
MoexiprilBetaxolol may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Betaxolol.
MoricizineMoricizine may increase the hypotensive activities of Betaxolol.
MorphineThe metabolism of Morphine can be decreased when combined with Betaxolol.
MoxonidineBetaxolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Betaxolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Betaxolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Betaxolol.
NadololBetaxolol may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Betaxolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.
NaproxenNaproxen may decrease the antihypertensive activities of Betaxolol.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Betaxolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Betaxolol.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Betaxolol.
NebivololNebivolol may increase the hypotensive activities of Betaxolol.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Betaxolol.
NeostigmineNeostigmine may increase the bradycardic activities of Betaxolol.
NepafenacNepafenac may decrease the antihypertensive activities of Betaxolol.
NesiritideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nesiritide.
NetupitantThe metabolism of Netupitant can be decreased when combined with Betaxolol.
NevirapineThe metabolism of Betaxolol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Betaxolol.
NicardipineBetaxolol may increase the hypotensive activities of Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Betaxolol.
NicorandilNicorandil may increase the hypotensive activities of Betaxolol.
NicotineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Betaxolol.
NifedipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Betaxolol.
NiguldipineBetaxolol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Betaxolol can be decreased when combined with Nilotinib.
NilvadipineBetaxolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Betaxolol.
NimodipineBetaxolol may increase the hypotensive activities of Nimodipine.
NisoldipineBetaxolol may increase the hypotensive activities of Nisoldipine.
NitrendipineBetaxolol may increase the hypotensive activities of Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Betaxolol.
NitroglycerinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitroglycerin.
NitroprussideBetaxolol may increase the hypotensive activities of Nitroprusside.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
NorepinephrineBetaxolol may decrease the bronchodilatory activities of Norepinephrine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Betaxolol.
ObinutuzumabBetaxolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Betaxolol.
OctreotideOctreotide may increase the bradycardic activities of Betaxolol.
OlanzapineThe serum concentration of Betaxolol can be increased when it is combined with Olanzapine.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Betaxolol.
OlmesartanBetaxolol may increase the hypotensive activities of Olmesartan.
OlodaterolBetaxolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Betaxolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Betaxolol.
OmapatrilatBetaxolol may increase the hypotensive activities of Omapatrilat.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Betaxolol.
OrciprenalineBetaxolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Betaxolol.
OsimertinibThe serum concentration of Betaxolol can be decreased when it is combined with Osimertinib.
OuabainBetaxolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Betaxolol.
OxprenololBetaxolol may increase the hypotensive activities of Oxprenolol.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Betaxolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Betaxolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Betaxolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Betaxolol.
PanobinostatThe metabolism of Betaxolol can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Betaxolol.
PargylineBetaxolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Betaxolol can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Betaxolol.
PasireotideBetaxolol may increase the bradycardic activities of Pasireotide.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Betaxolol.
Peginterferon alfa-2bThe serum concentration of Betaxolol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololBetaxolol may increase the hypotensive activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Betaxolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Betaxolol.
PentoliniumBetaxolol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Betaxolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Betaxolol.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Betaxolol.
PerindoprilBetaxolol may increase the hypotensive activities of Perindopril.
PerphenazinePerphenazine may increase the hypotensive activities of Betaxolol.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Betaxolol.
PethidineThe metabolism of Pethidine can be decreased when combined with Betaxolol.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Betaxolol.
PhenelzinePhenelzine may increase the hypotensive activities of Betaxolol.
PhenforminThe metabolism of Phenformin can be decreased when combined with Betaxolol.
PheniprazinePheniprazine may increase the hypotensive activities of Betaxolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Betaxolol.
PhenoxybenzamineBetaxolol may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Betaxolol.
PhentolamineBetaxolol may increase the hypotensive activities of Phentolamine.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Betaxolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
PhenylpropanolamineBetaxolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Betaxolol.
PilocarpineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Betaxolol.
PinacidilBetaxolol may increase the hypotensive activities of Pinacidil.
PindololBetaxolol may increase the hypotensive activities of Pindolol.
PiperazineThe metabolism of Piperazine can be decreased when combined with Betaxolol.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Betaxolol.
PirbuterolBetaxolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Betaxolol.
PirlindolePirlindole may increase the hypotensive activities of Betaxolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Betaxolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Betaxolol.
PolythiazideBetaxolol may increase the hypotensive activities of Polythiazide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Betaxolol.
Poractant alfaBetaxolol may increase the bradycardic activities of Poractant alfa.
PrazosinBetaxolol may increase the hypotensive activities of Prazosin.
PrimaquineThe metabolism of Betaxolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Betaxolol.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Betaxolol.
ProcaterolBetaxolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Betaxolol.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Betaxolol.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Betaxolol.
PromazinePromazine may increase the hypotensive activities of Betaxolol.
PromethazinePromethazine may increase the hypotensive activities of Betaxolol.
PromethazineThe metabolism of Promethazine can be decreased when combined with Betaxolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Betaxolol.
PropafenoneThe serum concentration of Betaxolol can be increased when it is combined with Propafenone.
PropafenoneBetaxolol may increase the bradycardic activities of Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Betaxolol.
PropranololBetaxolol may increase the hypotensive activities of Propranolol.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Betaxolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Betaxolol.
PTC299PTC299 may decrease the antihypertensive activities of Betaxolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Betaxolol.
QuetiapineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quetiapine.
QuinaprilBetaxolol may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Betaxolol can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Betaxolol.
QuinineThe metabolism of Quinine can be decreased when combined with Betaxolol.
RamiprilRamipril may increase the hypotensive activities of Betaxolol.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Betaxolol.
RanolazineThe metabolism of Betaxolol can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Betaxolol.
RegorafenibRegorafenib may increase the bradycardic activities of Betaxolol.
RemikirenBetaxolol may increase the hypotensive activities of Remikiren.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Betaxolol.
repinotanThe metabolism of repinotan can be decreased when combined with Betaxolol.
RescinnamineBetaxolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Betaxolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Betaxolol.
RifampicinThe metabolism of Betaxolol can be increased when combined with Rifampicin.
RiociguatBetaxolol may increase the hypotensive activities of Riociguat.
RisperidoneBetaxolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.
RitodrineBetaxolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Betaxolol.
RituximabBetaxolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Betaxolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Betaxolol.
RolapitantThe metabolism of Betaxolol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Betaxolol can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Betaxolol.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Betaxolol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Betaxolol.
SafrazineSafrazine may increase the hypotensive activities of Betaxolol.
SalbutamolBetaxolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Betaxolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Betaxolol.
SalmeterolBetaxolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Betaxolol.
SaprisartanBetaxolol may increase the hypotensive activities of Saprisartan.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Betaxolol.
SecobarbitalSecobarbital may increase the hypotensive activities of Betaxolol.
SelegilineSelegiline may increase the hypotensive activities of Betaxolol.
SelexipagBetaxolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Betaxolol.
SertindoleThe metabolism of Sertindole can be decreased when combined with Betaxolol.
SertralineThe serum concentration of Betaxolol can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Betaxolol.
SildenafilSildenafil may increase the antihypertensive activities of Betaxolol.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Betaxolol.
SilodosinBetaxolol may increase the orthostatic hypotensive activities of Silodosin.
SimeprevirThe metabolism of Betaxolol can be decreased when combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Betaxolol.
SitaxentanBetaxolol may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Betaxolol.
SpiraprilBetaxolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Spironolactone.
SRT501SRT501 may decrease the antihypertensive activities of Betaxolol.
StiripentolThe metabolism of Betaxolol can be decreased when combined with Stiripentol.
SufentanilBetaxolol may increase the bradycardic activities of Sufentanil.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Betaxolol.
SulindacSulindac may decrease the antihypertensive activities of Betaxolol.
SuprofenSuprofen may decrease the antihypertensive activities of Betaxolol.
TacrineTacrine may increase the bradycardic activities of Betaxolol.
TadalafilTadalafil may increase the antihypertensive activities of Betaxolol.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Betaxolol.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Betaxolol.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Betaxolol.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Betaxolol.
TelmisartanBetaxolol may increase the hypotensive activities of Telmisartan.
TemocaprilBetaxolol may increase the hypotensive activities of Temocapril.
TenofovirThe metabolism of Betaxolol can be decreased when combined with Tenofovir.
TenoxicamTenoxicam may decrease the antihypertensive activities of Betaxolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Betaxolol.
TerazosinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Terazosin.
TerbinafineThe metabolism of Betaxolol can be decreased when combined with Terbinafine.
TerbutalineBetaxolol may decrease the bronchodilatory activities of Terbutaline.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Betaxolol.
TeriflunomideThe serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.
TerlipressinBetaxolol may increase the hypotensive activities of Terlipressin.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Betaxolol.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Betaxolol.
TheophyllineThe metabolism of Betaxolol can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Betaxolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Betaxolol.
ThiopentalThiopental may increase the hypotensive activities of Betaxolol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Betaxolol.
ThioridazineThioridazine may increase the hypotensive activities of Betaxolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Betaxolol.
TiboloneBetaxolol may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Betaxolol can be decreased when combined with Ticlopidine.
TicrynafenBetaxolol may increase the hypotensive activities of Ticrynafen.
TimololBetaxolol may increase the hypotensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Betaxolol.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Betaxolol.
TizanidineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Tizanidine.
TofacitinibTofacitinib may increase the bradycardic activities of Betaxolol.
TolazamideBetaxolol may increase the hypoglycemic activities of Tolazamide.
TolazolineBetaxolol may increase the hypotensive activities of Tolazoline.
TolbutamideBetaxolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Betaxolol.
TolmetinTolmetin may decrease the antihypertensive activities of Betaxolol.
ToloxatoneToloxatone may increase the hypotensive activities of Betaxolol.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Betaxolol.
TorasemideBetaxolol may increase the hypotensive activities of Torasemide.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Betaxolol.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Betaxolol.
TrandolaprilBetaxolol may increase the hypotensive activities of Trandolapril.
TranilastTranilast may decrease the antihypertensive activities of Betaxolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Betaxolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Betaxolol.
TravoprostBetaxolol may increase the hypotensive activities of Travoprost.
TrazodoneThe serum concentration of Betaxolol can be increased when it is combined with Trazodone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Betaxolol.
TreprostinilBetaxolol may increase the hypotensive activities of Treprostinil.
TriamtereneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Triamterene.
TrichlorfonTrichlorfon may increase the bradycardic activities of Betaxolol.
TrichlormethiazideBetaxolol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Betaxolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Betaxolol.
TrimazosinBetaxolol may increase the hypotensive activities of Trimazosin.
TrimethaphanBetaxolol may increase the hypotensive activities of Trimethaphan.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Betaxolol.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Betaxolol.
TubocurarineTubocurarine may increase the bradycardic activities of Betaxolol.
UdenafilUdenafil may increase the antihypertensive activities of Betaxolol.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Betaxolol.
UnoprostoneBetaxolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Betaxolol.
ValsartanValsartan may increase the hypotensive activities of Betaxolol.
VardenafilVardenafil may increase the antihypertensive activities of Betaxolol.
VareniclineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Varenicline.
VemurafenibThe serum concentration of Betaxolol can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Betaxolol can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Verapamil.
VilanterolBetaxolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Betaxolol can be increased when it is combined with Vilazodone.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Betaxolol.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Betaxolol.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Betaxolol.
VortioxetineThe serum concentration of Betaxolol can be increased when it is combined with Vortioxetine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Betaxolol.
XylometazolineBetaxolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Betaxolol.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Betaxolol.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Betaxolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Betaxolol.
ZileutonZileuton may decrease the antihypertensive activities of Betaxolol.
ZimelidineThe serum concentration of Betaxolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Betaxolol can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Betaxolol.
ZomepiracZomepirac may decrease the antihypertensive activities of Betaxolol.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Betaxolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. McLean AJ, Zeng FY, Behan D, Chalmers D, Milligan G: Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor. Mol Pharmacol. 2002 Sep;62(3):747-55. [PubMed:12181453 ]
  2. Rudoy CA, Van Bockstaele EJ: Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1119-29. Epub 2007 Apr 19. [PubMed:17513029 ]
  3. Satoh N, Suzuki J, Bessho H, Kitada Y, Narimatsu A, Tobe A: Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol. Jpn J Pharmacol. 1990 Oct;54(2):113-9. [PubMed:2077180 ]
  4. Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63. [PubMed:2891463 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Rait JL: Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Aust N Z J Ophthalmol. 1999 Feb;27(1):57-64. [PubMed:10080340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23